Peptides DB
Research-centric peptide and protocol reference hub

Cartalax (AED peptide) record · updated 7h ago

Healing & recoveryInflammation & immuneGrade C · preclinicalResearch use only
All 2 studiesJump to the evidenceCompare
What is Cartalax (AED peptide) used for?

Cartalax (AED) is a synthetic Khavinson tripeptide researched as a cartilage and connective tissue bioregulator, with most evidence drawn from Russian preclinical and gerontology work.

Primarily researched for · Healing & recovery

Development stage

where Cartalax (AED peptide) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 1 registered trial. It describes the research record, not a recommendation.

Identity
NameCartalax (AED peptide)
Full name—
Sequence—
ClassHealing
Research levelEmerging
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Healing & recovery: Healing 4.0, Muscle 1.0, Metabolic 1.0, Neuro 1.0, Sleep 0.0, Immune 3.0, Skin 2.0Healing & recovery — 4.0 / 5Muscle & body comp — 1.0 / 5Metabolic & appetite — 1.0 / 5Neuro & mood — 1.0 / 5Inflammation & immune — 3.0 / 5Skin & aesthetics — 2.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin4.01.01.01.00.03.02.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies2
Human / animal / cellular0 / 0 / 1
Highest trial phasePreclinical
Years covered2020–2022
Latest study14d ago
Publication history
20202022
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

2 rowsOpen in the library →
StudyTypeYearSummary depth
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers.
TakeawayThis review highlights the importance of POT and LAT transporters in the cellular transport of ultrashort peptides, but lacks specific data to support clinical applications.
review2022Full text read0.70
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
FindingTERT gene expression increased eightfold in 'stationary' aging cultures.
In vitro2020Full text read0.80

Articles mentioning Cartalax (AED peptide)